Cipla (CIPLA) — Financial Results

Cipla reported Q4 FY25 revenue of ₹6,730 crores, up 9% YoY, with PAT at INR 1,222 crores (18.2% margin) and EBITDA margin expanding 150 bps to 22.8%. Net cash stood at INR 10,369 crores against minimal debt of INR 438 crores. The company highlighted growth in branded prescription, trade generics, and respiratory pipelines, including Advair and nano paclitaxel launches, while noting U.S. market growth moderation to 8-10% industry rate. FY26 capex will focus on respiratory capacity expansion in India, U.S., and China at ~5% of revenue.

📄 View Original Announcement (PDF)

📊 Stock Analysis — CIPLA ✨ Ask AI About This

About Cipla Limited (CIPLA)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,15,682.55 Cr P/E: 25.4 ROE: 14.6% ROCE: 19.4%

View full CIPLA stock details →

📡 Get AI alerts when CIPLA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track CIPLA — Free

💡 Ask AI about this filing

"How does this financial results affect Cipla Limited's outlook?" "What did Cipla Limited announce on 16 May 2025?" "Is this positive or negative for CIPLA?"

Ask AI Free →

📊 More CIPLA filings

See all CIPLA filings →

🔥 Also filed on 16 May 2025

TATAPOWER Tata Power Company Limited Financial Results DELHIVERY Delhivery Limited Financial Results APOLLOHOSP Apollo Hospitals Enterprise Limited Corporate Action BRITANNIA Britannia Industries Limited Financial Results SHRIRAMFIN Shriram Finance Limited Corporate Action ICICIPRULI ICICI Prudential Life Insurance Company Limited Annual Report

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when CIPLA files new disclosures

Track CIPLA filings, board meetings, and corporate actions. Free email alerts at 5 PM.